Kyntra Bio, Inc. (KYNB) is a San Francisco-based biopharmaceutical company — formerly FibroGen — developing oncology and rare-disease therapies. Its analyst coverage is thin but generally constructive. Five verifiable price targets were reviewed: Oppenheimer at $35 (Outperform, initiated in mid-2026 and maintained in August), Rodman & Renshaw at $30 (Buy, June 2026), H.C. Wainwright at $43 (Buy, reiterated October 2026), Lake Street at $41 (Buy, September 2026), and Maxim at $35 (Buy, October 2026). The arithmetic mean of these five targets is $36.80, rounded to $37 for the central target, with a low-to-high range of $30 to $43.
Views differ mainly on how much credit to assign to FG-3246, a CD46-targeting antibody-drug conjugate (ADC) in Phase II for metastatic castration-resistant prostate cancer (mCRPC), and on the value of the company's cash. Most ratings are Buy or Outperform, with one Hold among recent reviews. This is a small sample, and no single figure should be treated as a guarantee.
The stock last traded near $3.90, within a 52-week range of $3.60 to $11.19. Reaching $37 would require a gain of roughly 850% from current levels — a very large move even by the standards of speculative biotechnology.
It is important to note that most targets were set when the stock traded around $7 to $8, before a decline of roughly half over recent months. The gap between the current price and the targets therefore reflects a falling share price more than a rising forecast, and several price targets may not yet have caught up with the slide. A path toward $37 would likely depend on positive clinical data that materially re-rates the company.
The 52-week low of $3.60 sits just below the current price and is the nearest support level; a decisive break below it would leave the stock in record territory. On the upside, the $5 and $10 round numbers, along with the prior high near $11.19, mark the most visible resistance zones before any move toward the $30s could be contemplated.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual analysts may apply different periods. For KYNB, the most important near-term items are the next quarterly report (estimated around November 20, 2026), any FG-3246 Phase II data updates, changes to analyst targets, and the company's cash-burn and funding plans.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot changing trends more efficiently. For investors following volatile small-cap biotech names like Kyntra Bio, automated signals can complement fundamental research.
The question of whether KYNB can reach $37 — the average of five analyst targets spanning $30 to $43 — hinges almost entirely on clinical execution and sentiment rather than current fundamentals. At roughly $3.90, the move required is enormous, and the targets themselves largely predate the stock's recent decline. Support comes from a strong cash position, a focused oncology pipeline, and persistent Buy ratings; the principal obstacles are clinical risk, thin liquidity, and targets that may not yet reflect the new price reality. Investors should monitor clinical updates, analyst revisions, and cash runway rather than treat any single figure as a forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, KYNB has been loosely correlated with ACXP. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if KYNB jumps, then ACXP could also see price increases.
| Ticker / NAME | Correlation To KYNB | 1D Price Change % | ||
|---|---|---|---|---|
| KYNB | 100% | -8.46% | ||
| ACXP - KYNB | 54% Loosely correlated | -1.89% | ||
| HYPD - KYNB | 48% Loosely correlated | +0.39% | ||
| KURA - KYNB | 34% Loosely correlated | N/A | ||
| KYTX - KYNB | 34% Loosely correlated | -1.74% | ||
| IMNM - KYNB | 31% Poorly correlated | -3.67% | ||
More | ||||